Clinical trials: Multiple Sclerosis, Secondary Progressive
Multiple Sclerosis
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better.
- Trial name
- NCT06220669
- Testing
- LY3541860
- Where
- 20 sites in United States, France and 5 more
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
The purpose of the study is to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose, and recommended therapeutic dose of intravenously administered MIS416 weekly in patients with chronic…
- Trial name
- NCT01191996
- Testing
- MIS416
- Where
- New Zealand
- Volunteers
- 34 people
- Sponsor
- Innate Immunotherapeutics
Multiple Sclerosis
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
The study goal is to establish the equivalence of pharmacokinetic (PK) properties, as well as the comparability of safety, immunogenicity (IG) and pharmacodynamics (PD) of the drug product RPH-035 (R-Pharm JSC, Russia) in…
- Trial name
- NCT07597668
- Testing
- RPH-035, Ocrevus®
- Where
- 23 sites in Russia
- Volunteers
- 180 people
- Sponsor
- R-Pharm
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Phase II Clinical Trial of OCH-NCNP1
This study is designed to assess the efficacy and safety of OCH-NCNP1 compared to placebo in subjects diagnosed with relapsing remitting multiple sclerosis (RRMS) and secondary progressive mltiple sclerosis (SPMS) .
- Trial name
- NCT04211740
- Testing
- OCH-NCNP1
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- National Center of Neurology and Psychiatry, Japan
Multiple Sclerosis
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
The purpose of the study is to evaluate if the higher dose can give greater efficacy without negative impact on the adverse event profile for patients with early secondary progressive Multiple Sclerosis (SPMS).
- Trial name
- NCT00313976
- Testing
- Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
- Where
- 7 sites in Denmark, Sweden
- Sponsor
- Bayer
Relapsing Forms of MS
Study of Diroximel Fumarate in the Real-World Setting
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice.
- Trial name
- NCT04746976
- Testing
- Diroximel Fumarate
- Where
- 18 sites in United States
- Volunteers
- 75 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Sensitivity of Motor Assessment in MS - a Prospective Cohort Study
The study explores the application of marker-less motion analysis (visual-perceptive computing, VPC) using a consumer grade infrared and video camera (Microsoft Kinect) for clinical assessment in MS.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Chronic Progressive
- Trial name
- MOTOSENS (NCT04993274)
- Testing
- PASS-MS
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Friedemann Paul
Multiple Sclerosis (MS), Multiple Sclerosis (MS) Relapsing Remitting
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography
This study aims to: analyze prospectively the prevalence of subclinical oculomotor disorders (OMDs) in different phenotypes of Multiple Sclerosis (MS) and to study correlations with brain MRI T2 data.
- Conditions
- Multiple Sclerosis (MS), Multiple Sclerosis (MS) Relapsing Remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- EYE-SEP (NCT04705610)
- Testing
- Video-oculography / Social cognition tasks / Neuropsychological evaluations
- Where
- Monaco
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Association de Recherche Bibliographique pour les Neurosciences
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cortical Lesions in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease, leading to inflammation and degeneration of neurons in the entire central nervous system (CNS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- CLiMS (NCT03653585)
- Where
- Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Multiple Sclerosis, Progressive
Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis
In this clinical trial, researchers are exploring a novel approach to delivering therapy directly into the spinal fluid, which surrounds and nourishes the brain and spinal cord.
- Trial name
- NCT06841068
- Testing
- Amniotic fluid or placental CD117 stem cells
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Cladribine Tablets as an Exit Therapy Strategy
The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discontinuation This observational…
- Conditions
- Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- CLADREXIT (NCT06887426)
- Testing
- Cladribine
- Where
- France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
The purpose of the study is to evaluate the efficacy and safety of subcutaneously administered cladribine versus placebo to stop inflammation and treat disease progression of non-active secondary progressive multiple sclerosis.
- Trial name
- CLASP-MS (NCT05961644)
- Testing
- Cladribine Subcutaneous Injection, 0.9% Chloride Injection Sodium
- Where
- Poland
- Volunteers
- 188 people
- Sponsor
- Institute of Psychiatry and Neurology, Warsaw
Multiple Sclerosis, Relapsing-Remitting
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
This study will investigate an experimental new drug, GSK1223249 in patients diagnosed with relapsing forms of multiple sclerosis.
- Trial name
- NCT01435993
- Testing
- GSK1223249
- Where
- 2 sites in Italy, Norway
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Libyan Multiple Sclerosis Registry Study
This study aims to understand differences in access to diagnosis and treatment for people with multiple sclerosis (MS) receiving care in Libya.
- Trial name
- NCT07264725
- Testing
- Disease-Modifying Therapies
- Where
- Libya
- Volunteers
- 369 people
- Sponsor
- University of Zintan
Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
The primary goal of the research cohort is to facilitate patient access to clinical trials testing new therapeutic interventions, or access to second- line treatments.
- Trial name
- PRC-REMS (NCT01044576)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Imperial College London
Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity.
- Conditions
- Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis
- Trial name
- NCT07426991
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in Germany
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis
Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis
This research study is being done to evaluate the safety of BHT-3009 alone and when combined with atorvastatin (Lipitor) in patients with multiple sclerosis (MS).
- Trial name
- NCT00103974
- Testing
- BHT-3009-01
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Bayhill Therapeutics
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with…
- Trial name
- NCT01982942
- Testing
- ibudilast
- Where
- 28 sites in United States
- Volunteers
- 255 people
- Sponsor
- MediciNova